Last reviewed 2026-04-22 · How we verify

Recaticimab and Statin

Recaticimab is a monoclonal antibody that inhibits IL-6 signaling to reduce inflammation, combined with a statin to manage lipid levels and provide cardiovascular protection.

Recaticimab is a monoclonal antibody that inhibits IL-6 signaling to reduce inflammation, combined with a statin to manage lipid levels and provide cardiovascular protection. Used for Cardiovascular disease with elevated inflammatory markers.

At a glance

Mechanism of action

Recaticimab blocks interleukin-6 (IL-6), a key pro-inflammatory cytokine, thereby reducing systemic inflammation. When combined with a statin (HMG-CoA reductase inhibitor), the regimen addresses both inflammatory and lipid-driven cardiovascular pathology, potentially reducing atherosclerotic progression and cardiovascular events.

Approved indications

• Cardiovascular disease with elevated inflammatory markers

Common side effects

• Infection risk (IL-6 inhibition)
• Muscle-related adverse events (statin)
• Elevated liver enzymes

Key clinical trials

• PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis (PHASE4)
• Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Recaticimab and Statin CI brief — competitive landscape report
• Recaticimab and Statin updates RSS · CI watch RSS
• Peking Union Medical College Hospital portfolio CI